Skip to main content
Cardiology and Therapy logoLink to Cardiology and Therapy
. 2026 Aug 27;15(Suppl 1):49–60. doi: 10.1007/s40119-026-00464-6

Survival in a Contemporary, Real-World, Matched Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated vs Not Treated with Tafamidis

Fabian aus dem Siepen 1,✉, Angela Dispenzieri 2, Mazen Hanna 3, Martin Carlsson 4, Pablo Garcia-Pavia 5
PMCID: PMC13690688  PMID: 42658465

Abstract

Introduction

Tafamidis is approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) and has shown a survival benefit in the phase 3 study ATTR-ACT and in real-world settings. This analysis compared survival in a contemporary, matched, real-world cohort of patients with ATTR-CM treated with tafamidis vs untreated.

Methods

Data were pooled from an early access cohort (NCT02791230) and from patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS; NCT00628745) in 2019–2023 with a mixed or predominantly cardiac phenotype. Propensity score matching (1:1) was performed to match treated and untreated patients in the pooled sample based on baseline age, New York Heart Association class, and phenotype. Treated patients received tafamidis at the approved dose for ATTR-CM.

Results

A total of 283 treated and 283 untreated patients were included. Of the 283 treated patients, 85 were from the early access cohort and 198 from THAOS. All untreated patients were from THAOS. In treated vs untreated patients, mean age at enrollment was 76.9 vs 77.4 years, 89.0% vs 83.4% were male, 11.0% vs 16.6% were female, and 80.9% vs 73.1% had wild-type ATTR-CM. Estimated adjusted survival probabilities for all-cause mortality for treated vs untreated patients were 90.2% vs 76.0% at 30 months and 85.3% vs 67.5% at 42 months. Treated patients had a 74% lower risk of all-cause mortality compared with untreated patients (hazard ratio 0.26; 95% confidence interval 0.13–0.51). No new safety signals were identified.

Conclusions

This matched-cohort analysis demonstrated improved survival in a contemporary, real-world cohort of patients with ATTR-CM receiving the approved dose of tafamidis compared with those untreated. These findings further extend the results of ATTR-ACT to contemporary populations of patients with ATTR-CM treated clinically with tafamidis and reinforce earlier real-world evidence supporting tafamidis use.

Trial Registration

Clinicaltrials.gov identifiers NCT00628745 and NCT02791230.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s40119-026-00464-6.

Keywords: ATTR-CM, Real-world evidence, Survival analysis, Propensity score matching, Tafamidis

Key Summary Points

Why carry out this study?
Tafamidis has demonstrated survival benefit in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), both in the phase 3 study ATTR-ACT and in real-world studies from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
The current study evaluates survival in real-world patients with ATTR-CM treated with tafamidis vs untreated using pooled THAOS and early access study data, enabling propensity score matching to enhance methodological rigor.
What was learned from this study?
This matched-cohort analysis demonstrated improved survival in contemporary, real-world patients with ATTR-CM treated with tafamidis vs untreated.
These findings extend ATTR-ACT results to a contemporary patient population and reinforce prior real-world evidence supporting tafamidis use.

Introduction

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease caused by the deposition of transthyretin (TTR) amyloid fibrils in the interstitial space of the myocardium [2–5]. These fibrils form when the native TTR tetramer dissociates into monomers that misfold and aggregate into amyloid [6]. Amyloid deposits in the myocardium lead to diastolic dysfunction and increased wall thickness, resulting in arrhythmias, conduction disorders, and progressive heart failure [4, 5]. Patients may also present with extracardiac signs and symptoms due to amyloid accumulation in other tissues [7]. ATTR-CM has two subtypes, wild-type and variant. Wild-type ATTR-CM (ATTRwt-CM) arises from age-related destabilization of the wild-type TTR protein, whereas variant ATTR-CM (ATTRv-CM) results from TTR variants that produce a less stable TTR protein [7, 8]. When left untreated, median survival is approximately 5 years for patients with ATTRwt-CM and 2.5–6 years for patients with ATTRv-CM, depending on the specific TTR variant [9].

Tafamidis was the first disease-modifying therapy to receive regulatory approval for the treatment of ATTR-CM and is the only oral TTR kinetic stabilizer administered once daily [10]. Approval of tafamidis meglumine 80 mg and the bioequivalent formulation tafamidis free acid 61 mg (tafamidis 80/61 mg) was based on results from the phase 3 Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT; NCT01994889). In ATTR-ACT, pooled tafamidis doses (20 mg and 80 mg) significantly reduced all-cause mortality (hazard ratio [HR] 0.70; 95% confidence interval [CI] 0.51–0.96) and the annual rate of cardiovascular-related hospitalizations (relative risk ratio 0.68; 95% CI 0.56–0.81) compared with placebo [11]. After completing ATTR-ACT, patients were eligible to enroll in an open-label, long-term extension (LTE) study, in which tafamidis could be administered for up to 60 months (NCT02791230). In an interim analysis from the LTE study with approximately 5 years of follow-up, patients who received continuous tafamidis 80/61 mg had reduced mortality compared with those who initially received placebo and later switched to tafamidis (HR 0.59; 95% CI 0.44–0.79) [12].

Real-world data from the Transthyretin Amyloidosis Outcomes Survey (THAOS; NCT00628745) support the long-term survival benefit of tafamidis in contemporary patients with ATTR-CM. Among patients with a predominantly cardiac phenotype enrolled in THAOS in 2019 or later, estimated survival at 42 months was 86.3% (95% CI 80.4–90.5) for those treated with the approved dose of tafamidis, compared with 67.3% (95% CI 56.9–75.8) for untreated patients [13]. A similar analysis of patients with a mixed phenotype showed estimated survival rates of 81.5% (95% CI 66.7–90.2) in treated patients vs 75.1% (95% CI 66.1–82.0) in untreated patients at 30 months [14].

Previous THAOS analyses provided important real-world insights, but interpretation was challenged by baseline differences between treated and untreated patients because matching was not feasible as a result of limited data availability. The current analysis evaluates survival using data pooled from THAOS and an independent cohort of the ATTR-ACT LTE study who received early access to tafamidis [15], enhancing methodological rigor relative to these prior analyses by applying propensity score matching.

Methods

Data Sources

THAOS was a global, longitudinal, observational phase 4 study of patients with transthyretin amyloidosis (including ATTR-CM and transthyretin amyloid polyneuropathy) and asymptomatic carriers of pathogenic TTR variants. Patients who were currently or previously treated with tafamidis, as well as tafamidis-naïve patients, were eligible to enroll. Patients in THAOS were not receiving any other investigational treatment for ATTR-CM, and data were censored during any period when a patient participated in another clinical trial. Further details of the design of THAOS and eligibility criteria have been published [16]. THAOS was initiated in December 2007 and completed on June 16, 2023, and remains the largest and longest transthyretin amyloidosis disease registry to date.

The early access cohort was an independent arm of the LTE study, established through a protocol amendment in 2018. The amendment allowed patients with ATTR-CM to receive early access to the approved tafamidis dose for up to 60 months, until the drug became commercially available by prescription in their region or the sponsor terminated the study. Patients could continue standard-of-care therapies alongside study treatment, with the exception of protocol-specific prohibited medications [15]. Patients in this cohort were treated between 2018 and 2023.

Patients

Patients in THAOS had a diagnosis of transthyretin amyloidosis confirmed either by a genotyped pathogenic TTR variant or, in the absence of a variant, by evidence of cardiac involvement on echocardiogram (defined by mean left ventricular wall thickness > 12 mm) together with either (1) amyloid identified in cardiac or non-cardiac biopsy tissue by mass spectrometry or immunohistochemistry or (2) amyloid in cardiac tissue indirectly confirmed by bone scintigraphy, with no evidence of light chain amyloidosis. Patients were further classified by phenotype as previously described [17]. This analysis included patients from THAOS who enrolled between 2019 and 2023, had a predominantly cardiac or mixed phenotype at enrollment, and either received only the approved dose of tafamidis while in THAOS (treated) or never received tafamidis before or during THAOS (untreated) (Fig. 1).

Fig. 1.

Fig. 1

Patient population. ATTR-CM transthyretin amyloid cardiomyopathy, THAOS Transthyretin Amyloidosis Outcomes Survey

Eligibility criteria for the early access cohort were minimal to allow an unrestricted population of patients with ATTR-CM to receive early access to tafamidis. These criteria have been published in detail [15]. Briefly, patients were required to have a documented diagnosis of ATTR-CM (no specific testing regimens were required), TTR genotyping, and appropriate laboratory testing to rule out light chain amyloidosis.

Pooling and Matching Procedure

Patients from THAOS were combined with patients from the early access cohort to form the pooled population. Since all patients from the early access cohort received tafamidis, the untreated population consisted exclusively of patients from THAOS (Fig. 1). For this analysis, treated was defined as having received the approved dose of tafamidis and untreated was defined as having never received tafamidis. Patients in both groups may have received standard-of-care therapies.

Patients in the pooled treated population were matched 1:1 to patients in the untreated population using a nearest neighbor propensity score matching procedure without replacement to ensure similarity between the treated and untreated groups at baseline. For treated patients, baseline was defined as the date of tafamidis initiation for those in the early access cohort, and as the later date of tafamidis initiation or THAOS enrollment for those in THAOS. For untreated patients, baseline was the date of THAOS enrollment. Seven covariates were considered for propensity score matching: sex, New York Heart Association (NYHA) class, phenotype (cardiac, mixed), age, estimated glomerular filtration rate, follow-up time, and modified body mass index. ATTR-CM diagnosed patients from the early access cohort were not assessed for phenotype and were all assumed to have a cardiac phenotype for the purpose of matching. Among the seven covariates, three (age, NYHA class, phenotype) were statistically significant predictors of treatment status, and a multivariate logistic regression model including these covariates was used to generate propensity scores. Following propensity score matching, the Kolmogorov–Smirnov test yielded a p value of 0.999, indicating that the distributions of propensity scores in the treated and untreated groups were statistically well balanced. The final study population was the 1:1 matched cohort (Fig. 1).

Outcomes and Statistical Analysis

Baseline demographic and clinical characteristics are reported as number (percentage) for categorical data and mean, standard deviation (SD), median, and 10th and 90th percentiles for continuous data. Continuous variables were analyzed using Welch’s t test, and categorical variables were compared using the chi-square test. For all analyses, a two-sided significance level of 0.05 was used, and a p value of < 0.05 was considered statistically significant.

Time-to-event analyses for all-cause mortality and cardiovascular-related mortality were conducted using stratified Cox proportional hazards models. Covariates for both models included treatment (treated vs untreated), phenotype (cardiac vs mixed), TTR genotype (wild-type vs variant), baseline NYHA class (I/II vs III), and sex (male vs female). The all-cause mortality model was additionally adjusted for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and troponin T concentration, both entered as quartiles. HRs and two-sided 95% CIs for treatment were derived from the models. All-cause mortality and cardiovascular-related mortality were further analyzed using the Kaplan–Meier method. Overall survival estimates and corresponding 95% CIs are presented at 30 and 42 months for each treatment group. All-cause mortality was also analyzed using the Kaplan–Meier method in treated and untreated patients by National Amyloidosis Centre (NAC) stage (I, II, III) and in patients with ATTRwt-CM only.

Safety data were collected prospectively from the time patients initiated tafamidis treatment or, for those already receiving tafamidis at enrollment in THAOS, from the time of enrolled consent. Data were collected through the end of the observation period of the study, which must have included at least 28 days after the last administration of tafamidis for patients in THAOS, and through 28 days after the last administration of tafamidis for patients in the early access cohort. Safety data are summarized descriptively.

Concomitant heart failure medications prior to and after tafamidis initiation for treated patients, and prior to and after enrollment for untreated patients, are summarized descriptively. Medications were classified into the following three categories: agents acting on the renin–angiotensin system, beta blockers, and diuretics.

Ethical Approval

Both studies were approved by the independent review board or ethics committee at each participating center. These studies were conducted in accordance with the concepts laid out in the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. All patients provided written informed consent.

Results

Patients

All patients from the early access cohort and all those from THAOS enrolled in 2019‒2023 with a predominantly cardiac or mixed phenotype were considered for matching (Fig. 1). After the matching procedure was applied, 283 treated and 283 untreated patients with ATTR-CM were included in this analysis. Among 283 treated patients, 198 were from THAOS and 85 were from the early access cohort. All 283 untreated patients were from THAOS.

In treated and untreated patients, respectively, mean age (SD) at enrollment was 76.9 (8.9) and 77.4 (9.3) years, 252 (89.0%) and 236 (83%) were male, 31 (11.0%) and 47 (16.6%) were female, and 229 (80.9%) and 207 (73.1%) had ATTRwt-CM (Table 1). Mean (SD) N-terminal pro-B-type natriuretic peptide was 4670 (5797.9) pg/mL (n = 167) and 4271 (6086.6) pg/mL (n = 203) in patients with available data. Mean (SD) follow-up time was 1.6 (1.1) years in both groups.

Table 1.

Demographics and baseline clinical characteristics

Characteristic Treated (n = 283) Untreated (n = 283) p value
Sex, n (%) 0.051
 Male 252 (89.0) 236 (83.4)
 Female 31 (11.0) 47 (16.6)
Age at enrollment, years
 Mean (SD) 76.9 (8.9) 77.4 (9.3) 0.515
 Median (10th, 90th percentile) 78.0 (66.1, 88.0) 78.7 (65.7, 88.3)
Age at diagnosis, years n = 197 n = 270
 Mean (SD) 76.7 (8.7) 76.3 (9.5) 0.593
 Median (10th, 90th percentile) 78.0 (65.6, 87.7) 77.3 (63.3, 87.7)
Time from diagnosis to enrollment, years n = 197 n = 270
 Mean (SD) 1.0 (1.4) 1.3 (1.7) 0.048
 Median (10th, 90th percentile) 0.5 (0.1, 2.6) 0.5 (0.1, 3.4)
Follow-up time, years
 Mean (SD) 1.6 (1.1) 1.6 (1.1) 0.672
 Median (10th, 90th percentile) 1.4 (0.3, 3.3) 1.4 (0.3, 3.5)
mBMIa n = 225 n = 181
 Mean (SD) 1144 (203.4) 1089 (231.2) 0.011
 Median (10th, 90th percentile) 1121 (914.1, 1417.0) 1058 (802.5, 1368.2)
eGFR, mL/min/1.73 m2 n = 266 n = 239
 Mean (SD) 57.6 (24.3) 55.5 (27.3) 0.359
 Median (10th, 90th percentile) 55.9 (29.9, 89.0) 52.7 (24.2, 88.9)
NT-proBNP, pg/mL n = 167 n = 203
 Mean (SD) 4670 (5797.9) 4271 (6086.6) 0.522
 Median (10th, 90th percentile) 2995 (487.0, 10,906) 2614 (413.0, 8905.0)
Troponin T, ng/mL n = 99 n = 178
 Mean (SD) 5339.5 (35,422.3) 4221.8 (18,749.0) 0.919
 Median (10th, 90th percentile) 53.7 (26.7, 136.0) 56.0 (16.0, 250.0)
NYHA class, n (%) 0.116
 I 56 (19.8) 40 (14.1)
 II 174 (61.5) 176 (62.2)
 III 53 (18.7) 67 (23.7)
NAC stage, n (%) n = 166 n = 200 0.108
 I 76 (45.8) 83 (41.5)
 II 62 (37.3) 65 (32.5)
 III 28 (16.9) 52 (26.0)
Genotype, n (%) 0.028
 Variant 54 (19.1) 76 (26.9)
 Wild-type 229 (80.9) 207 (73.1)
Phenotype, n (%) 1.000
 Cardiac 197 (69.6) 197 (69.6)
 Mixed 86 (30.4) 86 (30.4)

Number of patients with available data indicated for variables with missing data

BMI body mass index, eGFR estimated glomerular filtration rate, mBMI modified body mass index, NAC National Amyloidosis Centre, NT-proBNP N-terminal pro-B-type natriuretic peptide, NYHA New York Heart Association

amBMI is calculated by multiplying BMI (kg/m2) by serum albumin (g/L)

Among treated patients, 155 (54.8%) received heart failure medication prior to tafamidis treatment, and 51 (18.0%) received heart failure medication after tafamidis initiation (Tables S1 and S2). Among untreated patients, 105 (37.1%) received heart failure medication prior to enrollment, and 8 (2.8%) received heart failure medication after enrollment.

All-Cause Mortality

A total of 38 treated patients (13.4%) and 67 untreated patients (23.7%) died. The estimated adjusted survival probabilities for all-cause mortality for treated vs untreated patients were 90.2% vs 76.0% at 30 months and 85.3% vs 67.5% at 42 months. Treated patients had a 74% reduced risk of all-cause mortality compared with untreated patients (HR 0.26; 95% CI 0.13–0.51) (Fig. 2). In addition, patients with ATTRv-CM had a 78% reduced risk of all-cause mortality compared with patients with ATTRwt-CM (HR 0.22; 95% CI 0.06–0.72). Each quartile increase in NT-proBNP was associated with a 2.5-fold increase in risk of all-cause mortality (HR 2.48; 95% CI 1.77–3.47). Troponin T was not significantly associated with risk of all-cause mortality in adjusted analyses (HR 1.36; 95% CI 0.98–1.89).

Fig. 2.

Fig. 2

Adjusted survival plot for all-cause mortality. Plot and HR derived from Cox proportional hazards model controlling for phenotype, TTR genotype, baseline NYHA class, sex, NT-proBNP, and troponin T. CI confidence interval, HR hazard ratio, NT-proBNP N-terminal pro-B-type natriuretic peptide, NYHA New York Heart Association, TTR transthyretin

Kaplan–Meier estimated survival rates at 30 months were 79.4% (95% CI 71.5–85.3) for treated patients and 70.3% (95% CI 62.5–76.8) for untreated patients. Corresponding 42-month rates were 71.2% (95% CI 58.9–80.4) and 59.1% (95% CI 49.2–67.8).

In treated (n = 63) and untreated (n = 83) patients in NAC stage I, 30-month survival rates were 93.2% (95% CI 79.3–97.9) and 90.7% (95% CI 76.4–96.5) and 42-month survival rates were 93.2% (95% CI 79.3–97.9) and 82.7% (95% CI 63.7–92.3), respectively (Fig. S1). Survival rates in treated (n = 62) and untreated (n = 65) patients in NAC stage II were 84.2% (95% CI 63.2–93.8) and 69.7% (95% CI 52.5–81.7) at 30 months and 84.2% (95% CI 63.2–93.8) and 51.6% (95% CI 25.8–72.5) at 42 months (Fig. S2). In treated (n = 28) and untreated (n = 52) patients in NAC stage III, respectively, survival rates were 49.9% (95% CI 21.4–73.1) and 43.0% (95% CI 26.0–58.9) at 30 months and 49.9% (95% CI 21.4–73.1) and 30.7% (95% CI 13.8–49.5) at 42 months (Fig. S3).

In patients with ATTRwt-CM, Kaplan–Meier survival probabilities at 30 and 42 months, respectively, were 78.9% (95% CI 69.7–85.6) and 69.1% (95% CI 54.8–79.7) for treated patients (n = 229) and 68.5% (95% CI 59.6–75.9) and 56.9% (95% CI 45.8–66.6) for untreated patients (n = 207) (Fig. S4).

Cardiovascular-Related Mortality

Treated patients had a 58% reduced risk of cardiovascular-related mortality compared with untreated patients (HR 0.42; 95% CI 0.18–0.99). Patients with ATTRv-CM had a 61% reduced risk of cardiovascular-related mortality compared with patients with ATTRwt-CM (HR 0.39; 95% CI 0.19–0.81).

Kaplan–Meier estimated survival rates at 30 months were 97.4% (95% CI 92.8–99.1) and 92.1% (95% CI 87.1–95.2) in treated and untreated patients, respectively. Corresponding rates at 42 months were 97.4% (95% CI 92.8–99.1) and 88.7% (95% CI 81.0–93.4).

Safety

Overall, 140 (49.5%) treated patients had AEs and 93 (32.9%) had serious AEs (Table 2). Ten (3.5%) patients discontinued treatment (permanently or temporarily) as a result of AEs, and 8 (2.8%) discontinued the study as a result of AEs.

Table 2.

Summary of treatment-emergent AEs in treated patients

THAOS (n = 198) Early access cohort (n = 85) Total (n = 283)
AEs, n 191 490 681
Patients with AEs, n (%) 64 (32.3) 76 (89.4) 140 (49.5)
Patients with medication error events, n (%) 48 (24.2) 0 48 (17.0)
Patients with serious AEs, n (%) 54 (27.3) 39 (45.9) 93 (32.9)
Patients with severe AEs, n (%) 46 (23.2) 33 (38.8) 79 (27.9)
Patients who discontinued from study because of AEs, n (%) NA 8 (9.4) 8 (2.8)
Patients who discontinued treatment because of AEs but continued in the study,a n (%) 10 (5.1) 0 10 (3.5)

AE adverse event, NA not applicable, THAOS Transthyretin Amyloidosis Outcomes Survey

aIncludes temporary or permanent discontinuation

Discussion

This matched-cohort analysis from THAOS and an early access cohort demonstrated improved survival in a contemporary, real-world cohort of patients with ATTR-CM treated with the approved dose of tafamidis compared with matched patients who did not receive tafamidis. Treated patients had a 74% reduction in all-cause mortality risk and 58% reduction in cardiovascular-related mortality risk, with numerically higher Kaplan–Meier survival probabilities for treated vs untreated patients for both all-cause and cardiovascular-related mortality in the overall population, and numerically higher all-cause survival rates within NAC subgroups and in patients with ATTRwt-CM. These real-world results are consistent with another recent matched cohort analysis of patients with ATTRwt-CM conducted across 19 centers in Italy, in which tafamidis treatment was associated with lower rates of all-cause mortality (HR 0.55, 95% CI 0.39–0.77; p = 0.001), and findings were consistent across NAC stages (p-interaction = 0.94) [18].

The current findings build upon the results of ATTR-ACT [11, 19, 20] by evaluating a more recent and diverse cohort, including patients included in THAOS treated between 2019 and 2023 and early access patients treated between 2018 and 2023. The higher estimated survival rates observed in this contemporary patient population compared with those in ATTR-ACT [11] suggest that patient prognosis may be improving over time, potentially owing to increased disease awareness, earlier diagnosis, and timely initiation of treatment. Additionally, these results strengthen prior real-world evidence from THAOS [13, 14] by employing a matched design, thereby enhancing the robustness and generalizability of the survival benefit observed with tafamidis.

Safety data showed that tafamidis was associated with low rates of treatment discontinuation due to AEs. The rates of AEs and serious AEs were consistent with expectations for this patient population, and no new safety signals were identified.

This analysis has several strengths including the use of a contemporary real-world cohort of patients representative of the global ATTR-CM population today, and the application of a matching procedure to ensure balance between treated and untreated groups. However, there are several limitations. Treated patients were disproportionately represented from THAOS relative to the early access cohort, and the control group was exclusively drawn from THAOS. The observational nature of the study introduces the possibility of selection and/or ascertainment bias, as physicians were responsible for submitting patients to the registry and may have favored inclusion of certain patients based on disease severity, phenotype, treatment history, or other factors. Clinical data such as NT-proBNP concentration and NAC stage were missing for a substantial proportion of patients, as is common with real-world disease registries. The treated and untreated cohorts were not balanced on NAC stage; however, an additional analysis of all-cause mortality was conducted in NAC stage subgroups and showed similar patterns to the overall cohorts, suggesting that the imbalance in NAC stage did not affect the observed treatment effect. Concomitant medication use differed between groups, and details on non-specific heart failure were limited. Specifically, patients in the treated group were more likely to receive concomitant heart failure medication, which may have contributed to improved outcomes. These factors may also affect the generalizability of the findings to the broader ATTR-CM population. There is potential for immortal time bias because patients in the treated group had to survive long enough to receive treatment. Regarding the matching procedure, patients in the early access cohort were not assessed for phenotype and were all assumed to have a cardiac phenotype, introducing an inherent bias toward this classification. Additionally, patients were not matched on the basis of TTR genotype, as doing so would have significantly reduced the sample size. However, TTR genotype was included as a covariate in the Cox model for all-cause mortality to account for its potential influence. Despite these limitations, these data strongly support the efficacy and safety of tafamidis in a real-world cohort with significantly different characteristics compared with the ATTR-ACT population.

Conclusion

Results from this matched-cohort analysis strengthen the evidence for a survival benefit in contemporary, real-world patients with ATTR-CM treated with tafamidis, with no new safety signals. These findings expand upon prior findings from ATTR-ACT and THAOS, providing further support for the effectiveness of tafamidis in routine clinical practice.

Supplementary Information

Below is the link to the electronic supplementary material.

Acknowledgements

We thank all patients and investigators from the THAOS registry and the early access study for their important contributions to this study.

Medical Writing, Editorial and Other Assistance

Medical writing support was provided by Emily Balevich, PhD, of Engage Scientific Solutions and was funded by Pfizer.

Author Contribution

Fabian aus dem Siepen, Angela Dispenzieri, Mazen Hanna, and Pablo Garcia-Pavia contributed to study conceptualization and investigation. Martin Carlsson conducted statistical analyses. All authors contributed to data interpretation and reviewed and approved the final version of the manuscript.

Funding

This study was sponsored by Pfizer. The study sponsor funded the journal’s Rapid Service Fee. This supplement has been sponsored by Pfizer.

Data Availability

Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See https://www.pfizer.com/science/clinical-trials/data-and-results for more information.

Declarations

Conflicts of Interest

Fabian aus dem Siepen reports speaker fees from Pfizer, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and Janssen, and consulting fees from Pfizer and Akcea Therapeutics. Angela Dispenzieri reports serving on advisory boards and independent review committees for Janssen; research funding from Alynlam, Pfizer, Takeda, BMS, and AbbVie; and serving on a scientific advisory board for HemalogiX. Mazen Hanna reports serving on advisory boards for Alnylam, Eidos, Ionis, Alexion Pharmaceuticals, and Pfizer. Martin Carlsson is an employee of Pfizer and holds stock/stock options in Pfizer. Pablo Garcia-Pavia reports speaker fees from Alnylam Pharmaceuticals, AstraZeneca, Bayer, BridgeBio, Intellia, Ionis Pharmaceuticals, Novo Nordisk, and Pfizer; consulting fees from Alexion, Alnylam Pharmaceuticals, AstraZeneca, Attralus, Bayer, BridgeBio, Intellia, Ionis Pharmaceuticals, Neurimmune, Novo Nordisk, and Pfizer; and research/educational support to his institution from Alnylam Pharmaceuticals, AstraZeneca, BridgeBio, Intellia, Novo Nordisk, and Pfizer.

Ethical Approval

Both studies were approved by the independent review board or ethics committee at each participating center. These studies were conducted in accordance with the concepts laid out in the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. All patients provided written informed consent.

Footnotes

Prior Presentation: Some of these data were presented at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain on August 31, 2025 [1].

References

  • 1.Aus Dem Siepen F, Dispenzieri A, Hanna M, et al. Survival in a contemporary, real-world, matched cohort of patients with transthyretin amyloid cardiomyopathy treated vs not treated with tafamidis. Eur Heart J. 2025. 10.1093/eurheartj/ehaf784.2696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–12. 10.1161/CIRCULATIONAHA.108.843334. [DOI] [PubMed] [Google Scholar]
  • 3.Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7(7):398–408. 10.1038/nrcardio.2010.67. [DOI] [PubMed] [Google Scholar]
  • 4.Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872–91. 10.1016/j.jacc.2019.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019;7(8):709–16. 10.1016/j.jchf.2019.04.010. [DOI] [PubMed] [Google Scholar]
  • 6.Powers ET, Amass L, Baylor L, Fernandez-Arias I, Riley S, Kelly JW. Transthyretin kinetic stabilizers for ATTR amyloidosis: a narrative review of mechanisms and therapeutic benefits. Cardiol Ther. 2025;14(3):333–50. 10.1007/s40119-025-00423-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Jain A, Zahra F. Transthyretin amyloid cardiomyopathy (ATTR-CM). Treasure Island: StatPearls; 2025. [PubMed] [Google Scholar]
  • 8.Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286–300. 10.1161/CIRCULATIONAHA.111.078915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16–26. 10.1161/CIRCULATIONAHA.118.038169. [DOI] [PubMed] [Google Scholar]
  • 10.Ioannou A. Evolution of disease-modifying therapy for transthyretin cardiac amyloidosis. Heart Int. 2024;18(1):30–7. 10.17925/HI.2024.18.1.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–16. 10.1056/NEJMoa1805689. [DOI] [PubMed] [Google Scholar]
  • 12.Elliott P, Drachman BM, Gottlieb SS, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15(1):e008193. 10.1161/CIRCHEARTFAILURE.120.008193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Garcia-Pavia P, Kristen AV, Drachman B, et al. Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). J Card Fail. 2025;31(3):525–33. 10.1016/j.cardfail.2024.06.003. [DOI] [PubMed] [Google Scholar]
  • 14.Wixner J, Dispenzieri A, Amass L, et al. Survival in a contemporary, real-world cohort of patients with mixed-phenotype transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from THAOS. Cardiol Ther. 2025. 10.1007/s40119-025-00421-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Crespo-Leiro MG, Hanna M, Damy T, et al. Early access to tafamidis for patients with transthyretin amyloid cardiomyopathy. JACC Adv. 2025;4(10 Pt 2):102122. 10.1016/j.jacadv.2025.102122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Plante-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T. The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin. 2013;29(1):77–84. 10.1185/03007995.2012.754349. [DOI] [PubMed] [Google Scholar]
  • 17.Gentile L, Coelho T, Dispenzieri A, et al. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Orphanet J Rare Dis. 2023;18(1):350. 10.1186/s13023-023-02962-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Porcari A, Milani P, Longhi S, et al. Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. Eur J Heart Fail. 2025. 10.1002/ejhf.70071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Damy T, Angeli FS, Wang R, Maurer MS, Fontana M. Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baseline. Eur Heart J. 2024. 10.1093/eurheartj/ehae666.1063. [DOI] [Google Scholar]
  • 20.Damy T, Wang R, Maurer MS, Gillmore JD, Fontana M. Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage. Eur J Heart Fail. 2025;27(12):2998–3009. 10.1002/ejhf.3696. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data Availability Statement

Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See https://www.pfizer.com/science/clinical-trials/data-and-results for more information.


Articles from Cardiology and Therapy are provided here courtesy of Springer

RESOURCES